Massimo Cristofanilli, MD, FACP, serves as the director of breast medical oncology, the associate director of precision oncology at the Meyer Cancer Center (MCC), and the coleader of the MCC Breast Cancer Disease Management Team, as well as the ccientific director of the Englander Institute of Precision Medicine.
Case 3: Role of Preoperative Endocrine Therapy in HR+ High-Risk Breast Cancer
Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, comment on the role of preoperative endocrine therapy in HR-positive high-risk breast cancer.
Case 3: POETIC and ADAPT Trials in HR+ High-Risk Breast Cancer
Joyce O’Shaughnessy, MD, reviews the case of a 42-year-old woman with node-positive, HR-positive high-risk breast cancer and discusses clinical data from the POETIC and ADAPT clinical trials.
Case 2: Recommendations for Approaching Treatment of HR+ Breast Cancer
A panel of breast cancer experts share recommendations for adjuvant chemotherapy and endocrine therapy for a patient with HR-positive breast cancer and discuss approaches to toxicity management to increase adherence to therapy.
Case 2: SABCS 2021 Updates on SOFT and TEXT Trials for HR+ Breast Cancer
Joyce O’Shaughnessy, MD, leads a discussion on SABCS 2021 updates from the SOFT and TEXT trials for premenopausal women with HR-positive breast cancer.
Case 2: HR+ High-Risk Breast Cancer
Experts in breast cancer review the case of a 42-year-old woman with grade 2, node-positive invasive ductal carcinoma and discuss updated data from the RxPONDER trial on adjuvant chemotherapy benefit in premenopausal women.
Case 1: Clinical Implications From MonarchE in HR+ Early Breast Cancer
Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, share insight on applying data presented from the monarchE study and the use of adjuvant abemaciclib in clinical practice for high-risk, HR+ early breast cancer.
Case 1: Role of Ki67 Testing in HR+ Early Breast Cancer
Sunil Badve, MD, FRCPath, and Heather McArthur, MD, evaluate best practices around Ki67 assessment when approaching treatment for HR+ early breast cancer.
Case 1: Using Adjuvant Abemaciclib for High-Risk HR+ Early Breast Cancer
Joyce O’ Shaughnessy, MD; Sunil Badve, MD, FRCPath; and Massimo Cristofanilli, MD, FACP, consider the role of adjuvant abemaciclib plus endocrine therapy for the treatment of patients with high-risk, node-positive, HR+ early breast cancer.
Case 1: MonarchE Study in High-Risk, HR+ Early Breast Cancer
Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’ Shaughnessy, MD, review the study design and clinical implications from the monarchE study for high-risk, HR+ early breast cancer.
Case 1: High-Risk, HR+/HER2- Early-Stage Breast Cancer
Experts in breast cancer review the case of a 54-year-old postmenopausal woman with stage IIB, high-risk, HR+ early-stage breast cancer and discuss factors to consider when assessing risk for systemic occurrence.
Next Steps Following PALOMA3 Trial for Breast Cancer
June 23rd 2015Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, Jefferson University Hospital, discusses the next steps following the PALOMA3 trial, which was a randomized, placebo-controlled phase III study examining palbociclib plus fulvestrant in pre- and post-menopausal patients with ER-positive breast cancer.